Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 | --- | --- | |----------------------------------------------------------------------------------------------|------- ...

Exhibit 99.1 Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update - Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma ("HCC)" study demonstrating: • Survival benefit maintained across key subpopulations • a six-month improvement over control arm in median survival • a strong 0.65 hazard ratio, maintained since 0.59 observed 10 months earlier - Advancing amezalpat towards a pivotal Phase 3 trial in first-line HCC - Pl ...

InvestorPlace is home to all of the hottest stock market coverage that traders need to know about on Thursday! Among this is what's going on with SMX (Security Matters) (NASDAQ:SMX) stock today, the biggest premarket stock movers this morning and more. All of this info is ready to go at the links below! Tempest Therapeutics will be holding a conference call at 8:30 a.m. Eastern Time today. This will cover its Phase 1b/2 combination study of amezalpat with atezolizumab and bevacizumab. How This Affects TPST ...

Core Insights - Tempest Therapeutics, Inc. is set to report new data from a global randomized Phase 1b/2 study involving amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab for the first-line treatment of hepatocellular carcinoma (HCC) on June 20, 2024 [1] Company Overview - Tempest Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class targeted and immune-mediated therapeutics for cancer treatment [3] - The company is advancing a diverse portfolio of small molecule product candidates that utilize tumor-targeted and/or immune-mediated mechanisms, with potential applications across a wide range of tumors [3] - Tempest Therapeutics is headquartered in Brisbane, California, and provides more information on its website [3]

About Tempest Therapeutics 1 If approved by the FDA BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 14,000 shares of its common stock under the Company's 2023 Inducement Plan. Sylv ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-35890 Tempest Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 45-1472564 | | --- | ...

Financial Performance - Tempest ended Q1 2024 with $32.3 million in cash and cash equivalents, down from $39.2 million at the end of Q4 2023[13] - The net loss for Q1 2024 was $7.9 million, or $0.36 per share, compared to a net loss of $7.6 million, or $0.55 per share, in Q1 2023[13] - Total liabilities decreased to $23.7 million as of March 31, 2024, from $24.8 million at the end of 2023[16] - The accumulated deficit increased to $173.2 million as of March 31, 2024, compared to $165.3 million at the end of 2023[16] - Tempest anticipates having sufficient resources to fund operations into the second quarter of 2025 based on its current cash and operating plan[13] Expenses - Research and development expenses for Q1 2024 were $4.3 million, a decrease from $4.7 million in Q1 2023, primarily due to reduced costs from contract research organizations[13] - General and administrative expenses increased to $3.6 million in Q1 2024 from $2.9 million in Q1 2023, mainly due to share-based compensation and consulting services[13] Clinical Development - Tempest plans to advance TPST-1120 into a pivotal Phase 3 trial in first-line hepatocellular carcinoma (HCC) and TPST-1495 into a Phase 2 study in Familial Adenomatous Polyposis (FAP) in 2024[5] - New preclinical data for TPST-1120 demonstrated significant anti-tumor activity in kidney cancer, showing reduced growth as a monotherapy and enhanced inhibition when combined with chemotherapy[6] - The company expects to announce updated data from the ongoing randomized study in first-line HCC patients in 2024[9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _______________________________________________________________________________________________________________________________ FORM 10-K _______________________________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO ...

Exhibit 99.1 Tempest Reports Year End 2023 Financial Results and Provides Business Update Brisbane, CA, March 19, 2024 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update. "2023 was a transformative year for Tempest. We announced strong positive randomized data showing the benefit of TPST-1120 combinatio ...

For the quarterly period ended September 30, 2023 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | | | Name of each exchange on which | | --- | --- | --- | | Title of each class | Trading Symbol(s) | registered | | Common Stock, $0.001 par value | TPST | The Nasdaq Stock Market LLC | | Series A Junior Partic ...